潜质未定克隆性造血致动脉粥样硬化及NLRP3炎性小体治疗作用研究进展

doi:10.20047/j.issn1673-7210.2023.21.08

Abstract
Figure/Table
References (34)
Related Citation (15)

Download: PDF (563 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract In recent years, some studies have shown that the increase of inflammatory markers, which results from the clonal hematopoiesis of indeterminate potential (CHIP) caused by somatic cell driven gene mutation, is one of the factors for the occurrence and development of atherosclerotic cardiovascular disease. The NLRP3 inflammasome in the Pyrin domain of the nucleotide-binding oligomeric domain-like receptor family, is an important regulator of pyroptosis and plays a key role in the inflammatory process. As a specific small-molecule inhibitor, MCC950 has a selective inhibitory effect on NLRP3 inflammasome mediated pyroptosis. Therefore, MCC950 is expected to become an effective drug for the clinical treatment of atherosclerotic cardiovascular diseases caused by inflammation mediated by CHIP. Starting from the related mutation of CHIP induced gene, this paper summarizes the pathogenesis of atherosclerosis mediated by the regulation of pyroptosis by NLRP3 inflammasome, and the role and mechanism of selective inhibitor MCC950 of NLRP3 inflammasome on the induction of atherosclerosis by CHIP, so as to provide a basis for clinical treatment of atherosclerosis.

Key words： Clonal hematopoiesis of indeterminate potential NLRP3 inflammasome Atherosclerosis Pyroptosis MCC950 Mutation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Yafang1 LI Si1 SHI Yang2 WEI Liping3

Cite this article:

CHEN Yafang1 LI Si1 SHI Yang2 WEI Liping3. Research progress on atherosclerosis induced by clonal hematopoiesis of indeterminate potential and the therapeutic effect of NLRP3 inflammasome[J]. 中国医药导报, 2023, 20(21): 40-44.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.21.08 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I21/40

[1] Libby P. The changing landscape of atherosclerosis [J]. Nature，2021，592（7855）：524-533.
[2] Steensma DP，Bejar R，Jaiswal S，et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes [J]. Blood，2015，126（1）：9-16.
[3] Jaiswal S，Libby P. Clonal haematopoiesis：connecting ageing and inflammation in cardiovascular disease [J]. Nat Rev Cardiol，2020，17（3）：137-144.
[4] Marnell CS，Bick A，Natarajan P. Clonal hematopoiesis of indeterminate potential （CHIP）：linking somatic mutations，hematopoiesis，chronic inflammation and cardiovascular disease [J]. J Mol Cell Cardiol，2021，161：98-105.
[5] Bhattacharya R，Zekavat SM，Haessler J，et al. Clonal hemat- opoiesis is associated with higher risk of stroke [J]. Stroke，2022，53（3）：788-797.
[6] Sano S，Oshima K，Wang Y，et al. Tet2-mediated clonal hem- atopoiesis accelerates heart failure through a mechanism involving the IL-1beta/NLRP3 inflammasome [J]. J Am Coll Cardiol，2018，71（8）：875-886.
[7] Murphy AJ，Dragoljevic D，Natarajan P，et al. Hematopoiesis of indeterminate potential and atherothrombotic risk [J]. Thromb Haemost，2022，122（9）：1435-1442.
[8] Jaiswal S，Natarajan P，Silver AJ，et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease [J]. N Engl J Med，2017，377（2）：111-121.
[9] Garcia-Outeiral V，de la Parte C，Fidalgo M，et al. The complexity of TET2 functions in pluripotency and development [J]. Front Cell Dev Biol，2020，8：630754.
[10] Fuster JJ，MacLauchlan S，Zuriaga MA，et al. Clonal hema- topoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice [J]. Science，2017，355（6327）：842-847.
[11] Venugopal K，Feng Y，Shabashvili D，et al. Alterations to DNMT3A in hematologic malignancies [J]. Cancer Res，2021， 81（2）：254-263.
[12] Cobo I，Tanaka T，Glass CK，et al. Clonal hematopoiesis driven by DNMT3A and TET2 mutations：role in monocyte and macrophage biology and atherosclerotic cardiovascular disease [J]. Curr Opin Hematol，2022，29（1）：1-7.
[13] Wang Y，Liu X，Shi H，et al. NLRP3 inflammasome，an immune-inflammatory target in pathogenesis and treatment of cardiovascular diseases [J]. Clin Transl Med，2020，10（1）：91-106.
[14] Groslambert M，Py BF. Spotlight on the NLRP3 inflammasome pathway [J]. J Inflamm Res，2018，11：359-374.
[15] Chen F，Chen ZQ，Zhong GL，et al. Nicorandil inhibits TLR4/MyD88/NF-kappaB/NLRP3 signaling pathway to reduce pyroptosis in rats with myocardial infarction [J]. Exp Biol Med（Maywood），2021，246（17）：1938-1947.
[16] Li L，Jiang M，Qi L，et al. Pyroptosis，a new bridge to tumor immunity [J]. Cancer Sci，2021，112（10）：3979-3994.
[17] He B，Nie Q，Wang F，et al. Role of pyroptosis in atherosclerosis and its therapeutic implications [J]. J Cell Physiol，2021，236（10）：7159-7175.
[18] van Hout GP，Bosch L，Ellenbroek GH，et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction [J]. Eur Heart J，2017，38（11）：828-836.
[19] Abplanalp WT，Cremer S，John D，et al. Clonal hematop- oiesis-driver DNMT3A mutations alter immune cells in heart failure [J]. Circ Res，2021，128（2）：216-228.
[20] Xu YJ，Zheng L，Hu YW，et al. Pyroptosis and its relationship to atherosclerosis [J]. Clin Chim Acta，2018，476：28-37.
[21] Zeng X，Liu D，Huo X，et al. Pyroptosis in NLRP3 inflammasome-related atherosclerosis [J]. Cell Stress，2022，6（10）：79-88.
[22] Qian Z，Zhao Y，Wan C，et al. Pyroptosis in the initiation and progression of atherosclerosis [J]. Front Pharmacol，2021， 12：652963.
[23] Yang Z，Shi J，Chen L，et al. Role of pyroptosis and ferroptosis in the progression of atherosclerotic plaques [J]. Front Cell Dev Biol，2022，10：811196.
[24] Bennett MR，Sinha S，Owens GK. Vascular smooth muscle cells in atherosclerosis [J]. Circ Res，2016，118（4）：692-702.
[25] Uddin M，Nguyen N，Yu B，et al. Clonal hematopoiesis of indeterminate potential，DNA methylation，and risk for coronary artery disease [J]. Nat Commun，2022，13（1）：5350.
[26] Bick AG，Pirruccello JP，Griffin GK，et al. Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis [J]. Circulation，2020，141（2）：124- 131.
[27] Dempsey C，Rubio AA，Bryson KJ，et al. Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-beta and cognitive function in APP/PS1 mice [J]. Brain Behav Immun，2017，61：306-316.
[28] Zhang L，Jiang YH，Fan C，et al. MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis [J]. Biomed Pharmacother，2021，143：112133.
[29] Coll RC，Robertson AA，Chae JJ，et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases [J]. Nat Med，2015，21（3）：248-255.
[30] Zhang Y，Lv X，Hu Z，et al. Protection of Mcc950 against high-glucose-induced human retinal endothelial cell dysfunction [J]. Cell Death Dis，2017，8（7）：e2941.
[31] Estruch R，Ros E，Salas-Salvado J，et al. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts [J]. N Engl J Med，2018，378（25）：e34.
[32] Ma Q，Fan Q，Han X，et al. Platelet-derived extracellular vesicles to target plaque inflammation for effective anti-atherosclerotic therapy [J]. J Control Release，2021，329：445-453.
[33] Zeng W，Wu D，Sun Y，et al. The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages [J]. Sci Rep，2021，11（1）：19305.
[34] Byrne NJ，Matsumura N，Maayah ZH，et al. Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 （nucleotide-binding domain-like receptor protein 3） inflammasome activation in heart failure [J]. Circ Heart Fail，2020，13（1）：e6277.